Phio Pharmaceuticals Q3 net loss widens 74% to $4.16 million

Bitget2026/11/05 21:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Phio Pharmaceuticals’ third-quarter 2026 net loss widened 74% year over year to $4.16 million due to higher research and development expenses.
Research and development spending more than doubled to $3.06 million, primarily driven by higher toxicology, drug-substance and clinical-supply costs.
Cash and cash equivalents fell 50% from December 31, 2025, to $10.61 million at September 30, 2026.
PH-762’s first commercial-scale cGMP drug-substance batch was released, supporting a Phase 2b study expected to begin in first-quarter 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611051605NEWSFILECNPR____20261105_322481_1) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Phio Pharmaceuticals Q3 net loss widens 74% to $4.16 million

You may also like

Crypto prices